The discovery of specific senescent immune cell markers could revolutionize how we target age-related liver disease and chronic inflammation. While senescent cells have long been implicated in aging, pinpointing which cellular populations drive specific pathologies has remained elusive—until now.
Salladay-Perez and colleagues used multiomic profiling to identify a distinct population of senescent macrophages characterized by dual expression of p21 and TREM2 proteins. These p21+TREM2+ macrophages accumulate in aging tissues and directly contribute to inflammaging—the chronic, low-grade inflammation that accelerates aging processes. The research demonstrates these cells specifically fuel metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as fatty liver disease, through sustained inflammatory signaling.
This finding represents a significant advancement in senescence biology because it moves beyond identifying senescent cells generally to characterizing functionally distinct senescent subtypes. The p21+TREM2+ signature provides a precise therapeutic target, potentially enabling selective elimination of pathogenic senescent macrophages while preserving beneficial immune functions. Given that MASLD affects nearly 40% of adults globally and lacks effective treatments, this mechanistic insight could inform new interventional strategies.
However, the research likely stems from controlled laboratory conditions, and translating these findings to human therapeutics remains complex. Macrophage biology varies significantly between tissues and disease states, and safely modulating senescent immune cells without compromising infection resistance requires careful consideration. The work nonetheless provides compelling evidence that not all senescent cells contribute equally to aging pathology—some may be more therapeutically relevant than others.
